Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Birth order

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    382 result(s) found for: Birth order. Displaying page 8 of 20.
    «« First « Previous 4  5  6  7  8  9  10  11  12  Next» Last»»
    EudraCT Number: 2005-002126-64 Sponsor Protocol Number: CA184-004 Start Date*: 2006-05-15
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: An Exploratory Study to Determine Potential Predictive Markers of Response and/or Toxicity in Patients with Unresectable Stage III or IV Malignant Melanoma Randomized and Treated with Ipilimumab (M...
    Medical condition: Melanoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed) SE (Completed) DK (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-000777-23 Sponsor Protocol Number: BSH-12 Start Date*: 2012-07-05
    Sponsor Name:Birken AG
    Full Title: Open, Blindly Evaluated, Prospective, Controlled, Randomized, Multicenter Phase III Clinical Trial to Compare Intra-individually the Efficacy and Tolerance of Oleogel-S10 versus Standard of Care in...
    Medical condition: Split-Thickness Skin Graft Donor Sites
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004865 10041667 Split thickness skin graft LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) FI (Completed) AT (Completed) BG (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2011-006134-17 Sponsor Protocol Number: IPM3002 Start Date*: 2012-07-30
    Sponsor Name:ZIOPHARM Oncology, Inc.
    Full Title: A Multi-center, Open-Label, Adaptive, Randomized Study of Palifosfamide-tris, a Novel DNA Crosslinker, in Combination with Carboplatin and Etoposide (PaCE) Chemotherapy versus Carboplatin and Etopo...
    Medical condition: Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041068 Small cell lung cancer extensive stage PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) HU (Completed) PL (Completed) IT (Completed) DE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2007-007869-21 Sponsor Protocol Number: VO59.08 Start Date*: 2008-08-27
    Sponsor Name:Stallergenes S.A.
    Full Title: A multi-national, randomised, double-blind, placebo-controlled, Phase II study to assess the efficacy and safety of three doses of sublingual immunotherapy administered as recombinant Bet v 1 table...
    Medical condition: Birch pollen rhinoconjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001728 Allergic rhinoconjunctivitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: LT (Completed) DE (Completed) FR (Completed) SE (Completed) FI (Completed) DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-003644-23 Sponsor Protocol Number: PTK0796-ABSI-1108 Start Date*: 2015-07-02
    Sponsor Name:Paratek Pharma LLC
    Full Title: A Phase 3 Randomized, Double-Blind, Multi-Center Study to Compare the Safety and Efficacy of Omadacycline IV/PO to Linezolid IV/PO for Treating Adult Subjects with Acute Bacterial Skin and Skin Str...
    Medical condition: Acute Bacterial Skin and Skin Structure Infection
    Disease: Version SOC Term Classification Code Term Level
    18.1 10021881 - Infections and infestations 10040872 Skin infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) HU (Completed) ES (Completed) PL (Completed) GR (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2018-003671-35 Sponsor Protocol Number: SPR994-301 Start Date*: 2019-04-18
    Sponsor Name:Spero Therapeutics, Inc.
    Full Title: A Phase 3, Randomized, Double-blind, Double-dummy, Multicenter, Prospective Study to Assess the Efficacy, Safety and Pharmacokinetics of Orally Administered Tebipenem Pivoxil Hydrobromide (SPR994) ...
    Medical condition: complicated urinary tract infection or acute pyelonephritis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10046571 Urinary tract infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed) LV (Completed) BG (Completed) HU (Completed) PL (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2006-001230-41 Sponsor Protocol Number: F02207GE304 Start Date*: 2006-08-17
    Sponsor Name:PIERRE FABRE MEDICAMENT
    Full Title: A EUROPEAN PHASE III, MULTICENTRE, DOUBLE-BLIND, RANDOMISED, MONOTHERAPY, 12-MONTH STUDY OF MILNACIPRAN FOR THE TREATMENT OF THE FIBROMYALGIA SYNDROME
    Medical condition: Fibromyalgia syndrome (FMS) is a common systemic rheumatologic disorder estimated to affect 2 to 4% of the population. Fibromyalgia is associated with a reduced threshold for pain, generally identi...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10016631 Fibromyalgia syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) FI (Completed) DE (Completed) GB (Prematurely Ended) DK (Prematurely Ended) PT (Completed) CZ (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-020371-22 Sponsor Protocol Number: UMCN-AKF 10.04 Start Date*: 2011-05-03
    Sponsor Name:Radboud University Nijmegen Medical Centre
    Full Title: Achieving appropriate exposuRe to RIBAvirin after a dose advise based on an abbreviated AUC of a first dose of ribavirin (ARRIBA)
    Medical condition: chronic HCV infection
    Disease: Version SOC Term Classification Code Term Level
    12.1 10019183 HCV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-005060-10 Sponsor Protocol Number: NVG09B113 Start Date*: 2013-04-08
    Sponsor Name:Novagali Pharma S.A.S.
    Full Title: A MULTICENTER, RANDOMIZED, DOUBLE-MASKED, 3 PARALLEL ARMS, PLACEBO CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF NOVA22007 1MG/ML (CICLOSPORIN/CYCLOSPORINE) EYE DROPS, EMULSION ADMINISTERED...
    Medical condition: Vernal Keratoconjunctivitis (VKC)
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004853 10057383 Allergic keratoconjunctivitis LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) IT (Completed) DE (Completed) PT (Completed) ES (Completed) GR (Completed) HR (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2021-003768-29 Sponsor Protocol Number: DAY101-102 Start Date*: 2022-04-05
    Sponsor Name:DOT Therapeutics-1 Inc. (Day One)
    Full Title: A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations
    Medical condition: Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-004696-12 Sponsor Protocol Number: FACIALPARALYSIS Start Date*: 2020-01-15
    Sponsor Name:AZIENDA OSPEDALIERA UNIVERSITARIA INTEGRATA VERONA
    Full Title: Clinical, Instrumental and Histological evaluation of the combined use of Onabotulinumtoxin A and hyaluronic acid fillers in patients with facial paralysis
    Medical condition: hemifacial paralysis (3 to 6 of the House-Brackmann scale)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004852 10016060 Facial palsy LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-005450-45 Sponsor Protocol Number: P04684 Start Date*: 2006-08-30
    Sponsor Name:Schering-Plough Research Institute
    Full Title: Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter/ Multinational, Efficacy and Safety Study of Desloratadine 5 mg in the Treatment of Subjects With Allergic Rhinitis Who Mee...
    Medical condition: Persistent Allergic Rhinitis (Allergic Rhinitis)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10039085 PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) PT (Completed) ES (Completed) DE (Completed) HU (Completed) SE (Completed) GR (Completed) DK (Completed) IT (Completed) BE (Completed) NL (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2020-000798-26 Sponsor Protocol Number: 20-AVP-786-306 Start Date*: 2021-06-22
    Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc.
    Full Title: A Phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of AVP-786 (deudextromethorphan hydrobromide [d6-DM]/quinidine sulfate [Q...
    Medical condition: Agitation in patients with dementia of the Alzheimer’s type
    Disease: Version SOC Term Classification Code Term Level
    21.1 10037175 - Psychiatric disorders 10001499 Agitation mental LLT
    20.0 10029205 - Nervous system disorders 10012271 Dementia Alzheimer's type PT
    20.0 10029205 - Nervous system disorders 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) PT (Trial now transitioned) PL (Trial now transitioned) DK (Trial now transitioned) BG (Trial now transitioned) GR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-000066-37 Sponsor Protocol Number: NM-V-101 Start Date*: 2013-01-16
    Sponsor Name:Nordmark Arzneimittel GmbH & Co. KG
    Full Title: Double-blind, randomized, placebo-controlled study on efficacy, safety and tolerability of ancrod in patients with sudden sensorineural hearing loss
    Medical condition: sudden sensorineural hearing loss (SSHL)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004854 10040016 Sensorineural hearing loss LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-003148-31 Sponsor Protocol Number: P05115 Start Date*: 2007-10-12
    Sponsor Name:Schering-Plough Research Institute, A Division of Schering Corporation
    Full Title: A Phase 4 Study of the Pharmacokinetics of Oral Posaconazole Among Patients with Compromised Gastrointestinal Function and at High Risk for Invasive Fungal Infection.
    Medical condition: Acute Myeloid Leukemia, Neutropenia, Antifungal Prophylaxis, Gastrointestinal Disorders
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000880 Acute myeloid leukaemia LLT
    9.1 10029354 Neutropenia LLT
    9.1 10049085 Antifungal prophylaxis LLT
    9.1 10017948 Gastrointestinal disorders NEC HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-004169-33 Sponsor Protocol Number: P04705 Start Date*: 2007-10-16
    Sponsor Name:Schering-Plough Research Institute, a division of Schering Corporation
    Full Title: A 52-Week Efficacy and Safety Non-Inferiority Study of Fluticasone Propionate/Salmeterol 250/50 mcg BID Delivered by Dry Powder Inhaler (DISKUS®) Versus Mometasone Furoate/Formoterol Fumarate 200/1...
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    8.1 10003553 Asthma LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Prematurely Ended) EE (Prematurely Ended) LT (Prematurely Ended) LV (Prematurely Ended) CZ (Prematurely Ended) DE (Prematurely Ended) SK (Completed) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-005669-37 Sponsor Protocol Number: 26866138-LYM-3002;Phase3 Start Date*: 2008-04-29
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Randomised, Open-Label, Multicentre Phase 3 Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone (VcR-CAP) or Rituximab, Cyclophosphamide, Doxorubicin, ...
    Medical condition: Patients with newly diagnosed Mantle Cell Lymphoma who are not eligible for bone marrow transplant. To determine which regimen of chemotherapy (VcR-CAP or R-CHOP) provides greater benefit in new...
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061275 Mantle cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) PT (Completed) CZ (Completed) AT (Completed) IT (Completed) HU (Completed) DE (Completed) ES (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2012-003354-89 Sponsor Protocol Number: 5172-035 Start Date*: 2013-03-28
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. USA
    Full Title: A Phase II Randomized Clinical Trial to Study the Efficacy and Safety of the combination regimen of MK-5172 and MK-8742 +/-Ribavirin (RBV) in Subjects with Chronic Hepatitis C Virus Infection
    Medical condition: Hepatitis C Virus Genotype 1 (HCV GT 1)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10019744 Hepatitis C PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) DK (Completed) HU (Completed) ES (Completed) SE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2011-000842-39 Sponsor Protocol Number: I2R-MC-BIAJ Start Date*: 2011-10-26
    Sponsor Name:Eli Lilly and Company
    Full Title: Protocol I2R-MC-BIAJ (a) A Comparison of LY2605541 Versus Insulin Glargine as Basal Insulin Treatment in Combination with Oral Anti-Hyperglycemia Medications in Insulin Naïve Patients with Type 2 ...
    Medical condition: Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10049746 Insulin-requiring type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) SK (Completed) GB (Completed) CZ (Completed) DE (Completed) LT (Completed) ES (Completed) GR (Completed) FI (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-000241-74 Sponsor Protocol Number: CNTO148AKS3001 Start Date*: 2014-12-30
    Sponsor Name:Janssen Biologics, BV
    Full Title: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects with Active Ankylosing Spondylitis
    Medical condition: Ankylosing spondylitis (AS)
    Disease: Version SOC Term Classification Code Term Level
    19.0 10028395 - Musculoskeletal and connective tissue disorders 10002556 Ankylosing spondylitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 4  5  6  7  8  9  10  11  12  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Jun 10 03:07:24 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA